C.R. Bard downgraded to Sell from Neutral at Goldman Goldman downgraded C.R. Bard to reflect increasing competitive pressures, reinvestment activity, and lowered assumptions for its peripheral drug eluting balloon. Price target lowered to $95 from $99.
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.